Press Release: BioAlliance Pharma : The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, and Topotarget A/S (NASDAQ OMX Copenhagen - TOPO), announce that the cross-border merger between the two companies is legally effective as of 22 July 2014 to create Onxeo, dedicated to orphan oncology diseases. BioAlliance Pharma, as the absorbing entity, will remain admitted to trading